Every AXLRx Spinal Muscular Atrophy report, across 9 report types and 3 markets. Each is scoped to your asset and verified to a live source.
Zolgensma's $2.125M one-time cost, outcomes-based Medicaid contracts, and Part B vs Part D routing across three SMA modalities.
SMN1/SMN2 biology, the Type 1–4 severity spectrum, and how newborn screening splits SMA into pre-symptomatic and symptomatic populations.
Three mechanisms, one SMN target — a one-time $2.125M gene therapy versus chronic intrathecal ASO and daily oral, and newborn screening resets the battlefield.
NPHC's negotiated Zolgensma price runs $1.5-1.8M against $2.125M US list, but the real mechanism is a 24-month motor-milestone rebate, the same structure now anchoring risdiplam and nusinersen pricing across the Gulf.
US SMA sizing splits into two live populations, not one number: 8,000-10,000 prevalent patients across Types 1-4, and a separate 500-700-patient Zolgensma-treated cohort now aging into a monitoring window where 15-20% show early motor plateau.
The UK SMA population is not one number. A ~1,000-patient actively-monitored NHS cohort and a 1,800-2,000-patient total prevalence estimate both appear across UK sources, and the gap between them is the pre-NBS legacy population outside the four specialist networks' active census.
GCC SMA incidence runs 1:6,000-8,000 against a global 1:10,000, and newborn-screening coverage splitting 90%/85%/75% across KSA/UAE/Qatar means the addressable near-term population depends on which country's screening curve a launch model assumes.
NICE's rejection-then-reversal of Zolgensma (2021→2023) established a Long-Term Value Framework precedent that now makes one-time gene therapy the NHS's preferred economic choice for newborn-screened SMA infants.
8,000-10,000 US SMA patients, a Type 1-4 severity split running roughly 60/27/13/under 5 percent, and the 500-700-patient Zolgensma cohort this funnel validates against.
A ~1,000-patient confirmed UK SMA cohort by type, reconciled against a 1,800-2,000-patient total prevalence estimate, and a 50-60/yr Zolgensma cohort as the on-therapy validation anchor.
GCC SMA incidence of 1:6,000-8,000 births, country-level newborn-screening coverage from 90% down to under 50%, an 800-1,200-patient legacy Type 2/3 pool, and a 60-80/yr Zolgensma cohort as the on-therapy anchor.
Four NHS Highly Specialised Services networks and six designated gene-therapy centres carry the UK SMA treatment pathway. This workbook sizes that institutional structure, plus the Bristol Institute of Child Health attenuation-cohort follow-up, before any physician name enters it.
Four designated GCC centres, KAMC, KFSH&RC in Riyadh, Sidra Medicine in Doha, and SKMC in Abu Dhabi, carry nearly all regional SMA gene-therapy and specialist referral activity. This workbook sizes that institutional concentration before any individual name enters it.
GCC SMA incidence running 1:6,000–8,000 births, newborn screening now covering up to 90% in leading states, and an 800–1,200-patient pre-NBS-era Type 2/3 cohort defining the chronic-therapy opportunity.
Why SMA is the most mature rare-disease access model in the GCC — all three modalities NPHC-covered, with Zolgensma's outcomes-based milestone rebate as the GCC-first template other programmes are built to follow.
All three SMA therapies cleared NICE with confidential PAS. The UK's 2021 newborn screening programme is now the real access lever, shifting competition to physician and family preference.
Why a mature 3-drug NICE framework leaves no room for parity entry, the Zolgensma-attenuation and Type 4 adult niches the current agents don't serve, and the NHS gene therapy centre capacity constraint every new gene therapy must plan around.
All three SMA mechanisms are formulary-listed in GCC — and outcomes-based rebate contracts now anchor Zolgensma's ~$1.5-1.8M price to a 24-month motor-milestone, following an NBS expansion generating 60-80 new gene-therapy candidates a year.
A fourth SMA drug has no room in the broad market — the opening is the 500–700-patient Zolgensma-attenuation cohort with no PA pathway yet.
NICE built UK SMA access in sequence: gene therapy took the pre-symptomatic subgroup first (HST15, HST24), then TA1162 moved chronic therapy to routine funding behind it. A new entrant inherits a fixed subgroup hierarchy and a comparator that shifts by population, not an open field.
The GCC SMA market already has three NPHC-covered agents spanning Types 1-3 — the constraint for a new entrant is finding one of exactly two open niches: the Zolgensma-attenuation cohort or undiagnosed adult-onset Type 4.
Europe's first national SMA newborn-screening programme, all three therapies NICE-recommended with commercial arrangements, and a living UK cohort of ~1,000 patients across four disease types.
Zolgensma's $2.125M sticker price obscures the real US SMA pricing lever: a 10-state Medicaid outcomes-based annuity paying $212,500 a year for ten years, set against chronic Spinraza and Evrysdi costs and a Part B/Part D routing split that changes patient cost by drug.
NICE rejected Zolgensma in 2021 on cost per QALY, then reversed in 2023 through its Long-Term Value Framework. That framework, not the PAS discount, is the real UK SMA pricing lever, and it sets an estimated £1.2-1.6M net cost against a £4.5-7.5M lifetime chronic-therapy alternative.
AXLRx publishes Payer & HTA, Disease Landscape, Competitive Intelligence, Pricing Strategy Model, Market Sizing Model, Patient Flow Model, KOL Mapping, Launch Readiness, and HTA Strategy Model for Spinal Muscular Atrophy. Each report is scoped to your asset, verified to a live source, and delivered in 72 hours.
Current Spinal Muscular Atrophy coverage spans United States, GCC (Gulf), and United Kingdom. Additional markets can be commissioned against the same evidence standard.
Every figure is cited to a live source at the point of writing and re-checked in an independent audit pass. The latest Spinal Muscular Atrophy reports were updated July 2026.